phenylbutazone--propyphenazone-drug-combination and Gout

Topics: Aminopyrine; Analgesics; Arthritis; Arthritis, Rheumatoid; Back Pain; Drug Combinations; Gout; Humans; Phenylbutazone; Rheumatic Diseases

Topics: Aminopyrine; Analgesics; Arthritis, Rheumatoid; Drug Combinations; Gout; Phenylbutazone; Spondylitis; Spondylitis, Ankylosing

A clinical evaluation of phenylbutazone and Butapyrin(R) (a mixture of phenylbutazone and aminopyrine) was made in 409 patients who had a variety of rheumatic diseases. Preliminary European claims were substantiated.In gout a specific favorable effect was brought about by phenylbutazone alone. Effects equivalent to the previously reported favorable response to Butapyrin (Irgapyrin) were observed when its constituent phenylbutazone was used alone. The drug had a suppressive effect in a high percentage of patients with rheumatoid arthritis, ankylosing spondylitis, arthritis with psoriasis and mixed arthritis (rheumatoid arthritis plus osteoarthritis). Favorable effect in peritendinitis of the shoulders, osteoporosis of the spine and acute lumbosacral strain also was noted. Toxicity resulted in discontinuance of medication in 10 per cent of patients with each drug. Manifestations of toxicity generally included fluid retention, nausea and rash, but there were several instances of transitory leukopenia and anemia. There was one instance of agranulocytosis with Butapyrin but none with phenylbutazone.dagger Aggravation of peptic ulcer occurred in ten patients with hemorrhage in two. Generally the toxicity was of a low order as compared with that of other drugs having an antirheumatic effect.

Topics: Aminopyrine; Analgesics; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Combinations; Gout; Humans; Osteoarthritis; Osteoporosis; Phenylbutazone; Rheumatic Diseases; Spondylitis, Ankylosing; Tenosynovitis